Background and Objective Atrial fibrillation (AF), the most common cardiac arrhythmia,
typically increases with age. Oral anticoagulants (OACs) are the cornerstone of treatment to …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Importance Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin
for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite …

Background Only 50% of atrial fibrillation (AF) patients recommended for oral
anticoagulation (OAC) use these medications, and less than half of them adhere to OAC. In …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Anticoagulant drugs directly or indirectly influence coagulation factors preventing fibrin
formation, thus preventing blood clotting. They are classified into two groups according to …

Introduction The objective of this study was to compare the risk of stroke in atrial fibrillation
(AF) with adherent use of oral anticoagulation (OAC), non-adherent use, and non-use of …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Introduction: Residual cardiovascular risk remains high in patients with atherosclerotic
cardiovascular disease despite current antithrombotic therapy. On the other hand, patients …

Aims Acenocoumarol is a vitamin‐K antagonist (VKA) primarily used in certain countries (eg
India, Netherlands, Spain). The half‐life of acenocoumarol is similar to that of non‐VKA oral …